Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates involves navigating volatility and inherent risks [1] Group 1: Company Overview - Idexx Laboratories (IDXX) is highlighted as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company operates in the animal diagnostic and health care sector, which is currently experiencing strong growth potential [3] Group 2: Earnings Growth - Idexx has a historical EPS growth rate of 11.4%, with projected EPS growth of 17.6% for the current year, surpassing the industry average of 14.8% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Idexx is currently at 6%, significantly higher than the industry average of -2.5% [5] - Over the past 3-5 years, Idexx has maintained an annualized cash flow growth rate of 14.6%, compared to the industry average of 6.3% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Idexx have been revised upward, with the Zacks Consensus Estimate increasing by 3.3% over the past month [8] Group 5: Investment Potential - Idexx has achieved a Growth Score of B and a Zacks Rank of 2, indicating its potential as an outperformer and a solid choice for growth investors [9][10]

Core Viewpoint - The market anticipates Idexx Laboratories (IDXX) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.31 per share, reflecting a year-over-year increase of +35.7% [3]. - Revenues are projected to reach $1.07 billion, which is a 6.3% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.74% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.34%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Idexx was expected to post earnings of $2.92 per share but actually delivered $2.96, resulting in a surprise of +1.37% [13]. - Over the past four quarters, Idexx has exceeded consensus EPS estimates three times [14]. Conclusion - Idexx is viewed as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance ahead of the earnings release [17].